The global burden of diabetes is increasing, with corresponding rises in the prevalence of diabetic retinopathy (DR), particularly among underserved populations with limited access to eye care services.^1-4 Early detection and timely intervention are critical to preventing vision loss; however, traditional in-person screening models often fail to reach high-risk populations because of geographic, socioeconomic, and system-level barriers.⁵

Telemedicine has emerged as a transformative approach in retinal care, particularly through remote imaging and screening programs.^6,7 By leveraging digital fundus photography, optical coherence tomography (OCT), and artificial intelligence (AI) assisted interpretation, teleretinal systems enable earlier detection of disease in settings with limited access to ophthalmic care.^8,9 These programs have been shown to improve screening rates, reduce disparities, and enhance efficiency within health care systems.¹⁰

This review examines the role of telemedicine in retinal care, with a focus on improving equity in DR detection. It reviews current models of teleretinal screening, evaluates their impact on access and clinical outcomes, and discusses cost-effectiveness, implementation challenges, and future directions.^6,11

Epidemiology and Burden of Diabetic Retinopathy

Disparities in DR prevalence and outcomes persist across socioeconomic and geographic lines.^1,5 Underserved populations including rural communities, low-income groups, and racial and ethnic minorities experience disproportionately higher rates of vision loss because of delayed diagnosis and limited access to care.⁵ Barriers such as transportation challenges, limited awareness, cost, and a shortage of specialists contribute to poor screening adherence.⁵As a result, many patients present with advanced disease that could have been mitigated with earlier detection and referral.² Telemedicine offers a means to address these disparities by decentralizing screening and bringing diagnostic capabilities closer to patients.^6,10

Telemedicine in Retinal Care: Models and Technologies

Teleretinal screening programs typically involve acquisition of retinal images at the point of care often in primary care clinics, community health centers, or mobile units followed by remote interpretation by trained readers or automated systems.^6,7 These models can be broadly categorized as synchronous (real-time) or asynchronous (store-and-forward), with the latter more commonly used in DR screening.⁷

Nonmydriatic fundus cameras have facilitated expansion of screening programs by enabling image capture without pharmacologic dilation, improving patient comfort and workflow efficiency.⁸ OCT integration further enhances diagnostic capability by enabling detection of diabetic macular edema (DME), a major cause of vision loss.⁹

Recent advances in AI have significantly augmented teleretinal programs. Deep learning algorithms have demonstrated high sensitivity and specificity for detecting referable DR, enabling scalable and cost-effective screening.^12,13 These systems can provide immediate results, facilitate timely referral and improve patient engagement.¹²

Improving Access to Care, Equity, and Health Disparities

One of the most significant contributions of telemedicine in retinal care is the expansion of access to screening services. By embedding retinal imaging within primary care settings, teleretinal programs reduce the need for patients to seek specialized care independently, thereby overcoming logistical barriers.¹⁰

In rural and remote areas, where ophthalmologists and optometrists may be scarce, telemedicine enables local health care providers to perform screening and connect patients with specialists as needed.¹⁴ Mobile and distributed screening models further extend reach to populations with limited health care infrastructure.^14,22

Studies have consistently demonstrated that teleretinal programs increase screening rates compared with traditional referral-based models.^10,19 Patients are more likely to undergo screening when it is offered during routine medical visits, reducing missed opportunities for early detection.¹⁰

Telemedicine has the potential to reduce health disparities by improving access to care for historically underserved populations.^5,15 By lowering structural barriers, teleretinal programs promote a more equitable distribution of health care services.¹⁰

However, achieving true equity requires careful program design. Factors such as digital literacy, language barriers, and trust in the health care system must be addressed to ensure successful implementation.^15,16 Community engagement and culturally competent care are essential components of effective telemedicine programs.¹⁵

Insurance coverage, reimbursement policy, and implementation support also influence access. Programs that integrate teleretinal screening into publicly funded health care systems or community-based initiatives are more likely to reach vulnerable populations.¹⁷ Although telemedicine can reduce disparities, it must be implemented alongside broader efforts to address social determinants of health.⁵

Clinical Effectiveness and Outcomes

Teleretinal screening has been shown to be highly effective in detecting DR and other retinal conditions. Sensitivity and specificity of telemedicine-based screening are comparable to in-person examinations when high-quality images are obtained and interpreted by trained readers or validated AI systems.^18,24

Importantly, telemedicine facilitates earlier detection of disease, allowing for timely intervention and improved visual outcomes. Patients identified with referable DR can be triaged efficiently, ensuring that those with vision-threatening disease receive prompt specialist care.^10,21

Integration of OCT into teleretinal programs enhances detection of diabetic macular edema (DME), which may not be apparent on fundus photography alone.⁹ This multimodal approach improves diagnostic accuracy and supports comprehensive retinal evaluation.^9,18 Longitudinal monitoring through telemedicine also enables ongoing assessment of disease progression, reducing the need for frequent in-person visits and improving patient adherence.¹⁰

Efficiency and Cost-Effectiveness

Telemedicine improves efficiency within health care systems by optimizing resource utilization. By triaging patients based on disease severity, teleretinal programs reduce unnecessary specialist visits and allow ophthalmologists to focus on patients requiring intervention.^10,19

Cost-effectiveness analyses have demonstrated that teleretinal screening is economically favorable, particularly in high-risk populations.^19,20 Early detection reduces the burden of advanced disease, lowering long-term health care costs associated with vision loss and disability.¹⁹

Workflow integration is a key factor in achieving efficiency. Automated image acquisition, AI-assisted grading, and streamlined referral pathways contribute to reduced turnaround times and improved patient outcomes.^12,13Additionally, telemedicine reduces indirect costs for patients, including travel expenses, time away from work, and caregiver burden.²⁰

Challenges and Limitations

Despite its advantages, telemedicine in retinal care faces several challenges. Image quality remains a critical factor, as suboptimal images can limit diagnostic accuracy and necessitate repeat examinations.^8,18 Training of personnel and robust quality assurance protocols are essential to maintain high standards.¹⁷

Technological barriers, including equipment costs and infrastructure requirements, may limit implementation in resource-constrained settings.^11,16 Connectivity issues, workflow integration, and data security concerns must also be addressed.¹⁶

Patient follow-up after screening remains a key challenge. Ensuring that patients with abnormal findings complete recommended referrals is essential for the effectiveness of teleretinal programs.²¹ Regulatory and reimbursement frameworks vary across regions, influencing program sustainability.¹⁷ Standardization of protocols and integration into health care systems are necessary to support widespread adoption.⁶

Future Directions

The future of telemedicine in retinal care is closely linked to continued advances in technology and health care delivery models. Artificial intelligence will continue to play a central role, with increasingly sophisticated algorithms capable of detecting multiple ocular and systemic conditions.^12,23

Integration of teleretinal programs with electronic health records and population health management systems will enhance coordination of care and support data-driven decision-making.¹¹ Portable and smartphone-based imaging devices hold promise for expanding access in low-resource settings.²² These technologies may enable large-scale screening initiatives in regions with limited infrastructure.^14,22

Telemedicine may also evolve to include remote monitoring and longitudinal management of retinal disease, reducing the need for frequent in-person visits.¹¹ Collaboration among health care providers, policymakers, and technology developers will be essential to maximize the impact of telemedicine on retinal health.^11,15

Conclusion

Telemedicine has transformed the landscape of retinal care by improving access, promoting equity, and enhancing efficiency in the detection and management of DR. Remote screening programs have demonstrated the ability to reach underserved populations, increase screening adherence, and facilitate earlier intervention, ultimately reducing the burden of vision loss.

Although challenges remain, particularly related to quality assurance, follow-up, and equitable implementation, the benefits of teleretinal programs are substantial. A mechanism-based and patient-centered approach, supported by technological innovation and integrated care models, is essential to realizing the full potential of telemedicine.

As the prevalence of diabetes continues to rise, telemedicine will play an increasingly important role in addressing disparities and improving outcomes in retinal care. Ophthalmologists, optometrists, and other eyecare providers are uniquely positioned to lead these efforts, leveraging telehealth technologies to deliver accessible, efficient, and high-quality care to diverse populations. RP

Nnamdi Elem Okore, OD, is a licensed optometrist in the United States and Canada with a clinical and research focus on retinal diseases, teleoptometry, and improving access to eye care in underserved populations. He reports no disclosures. Reach him at okorennamdi@gmail.com.

References

1. Bourne RRA, Steinmetz JD, Flaxman S, et al; Vision Loss Expert Group. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144-e160. doi:10.1016/S2214-109X(20)30489-7.

2. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-136. doi:10.1016/S0140-6736(09)62124-3.

3. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. International Diabetes Federation; 2021.

4. Yau JWY, Rogers SL, Kawasaki R, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564. doi:10.2337/dc11-1909.

5. Saydah SH, Gerzoff RB, Saaddine JB, Zhang X. Eye care among US adults at high risk for vision loss in the United States, 2002-2017. JAMA Ophthalmol. 2020;138(5):479-489. doi:10.1001/jamaophthalmol.2020.0192.

6. Silva PS, Cavallerano JD, Aiello LM, Aiello LP. Telemedicine and diabetic retinopathy: moving beyond retinal screening. Arch Ophthalmol. 2011;129(2):236-242. doi:10.1001/archophthalmol.2010.365.

7. Zimmer-Galler IE, Kimura AE, Gupta S. Diabetic retinopathy screening and the use of telemedicine. Curr Opin Ophthalmol. 2015;26(3):167-172. doi:10.1097/ICU.0000000000000150.

8. Cavallerano JD, Conlin PR, Tollefson SM, et al. Nonmydriatic digital imaging alternative for annual retinal examination in persons with previously documented no or mild diabetic retinopathy. Ophthalmology. 2005;112(10):1641-1647. doi:10.1016/j.ophtha.2005.04.010.

9. Virgili G, Menchini F, Casazza G, et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev. 2015;(1):CD008081. doi:10.1002/14651858.CD008081.pub3.

10. Mansberger SL, Sheppler C, Barker G, et al. Long-term comparative effectiveness of telemedicine in providing diabetic retinopathy screening examinations: a randomized clinical trial. JAMA Ophthalmol. 2015;133(5):518-525. doi:10.1001/jamaophthalmol.2015.1.

11. Li JPO, Liu H, Ting DSW, et al. Digital technology, tele-medicine and artificial intelligence in ophthalmology: a global perspective. Prog Retin Eye Res. 2021;82:100900. doi:10.1016/j.preteyeres.2020.100900.

12. Gulshan V, Peng L, Coram M, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA. 2016;316(22):2402-2410. doi:10.1001/jama.2016.17216.

13. Abràmoff MD, Lavin PT, Birch M, Shah N, Folk JC. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ Digit Med. 2018;1:39. doi:10.1038/s41746-018-0040-6.

14. Bai VT, Murali V, Kim R, Srivatsa SK. Teleophthalmology-based rural eye care in India. Telemed J E Health. 2007;13(3):313-321. doi:10.1089/tmj.2006.0054.

15. Bressler NM. Telemedicine and health care disparities in diabetic retinopathy screening. JAMA. 2020;323(19):1905-1906. doi:10.1001/jama.2020.2704.

16. Kruse CS, Krowski N, Rodriguez B, Tran L, Vela J, Brooks M. Telehealth and patient satisfaction: a systematic review and narrative analysis. BMJ Open. 2017;7(8):e016242. doi:10.1136/bmjopen-2017-016242.

17. Horton MB, Silva PS, Cavallerano JD, et al. Practice guidelines for ocular telehealth-diabetic retinopathy, third edition. Telemed J E Health. 2020;26(4):495-543. doi:10.1089/tmj.2020.0006.

18. Scanlon PH, Aldington SJ, Leal J, et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Diabet Med. 2015;32(2):200-207. doi:10.1111/dme.12612.

19. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283(7):889-896. doi:10.1001/jama.283.7.889.

20. Kirkizlar E, Serban N, Sisson JA, Swann JL, Barnes CS, Williams MD. Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration. Ophthalmology. 2013;120(12):2604-2610. doi:10.1016/j.ophtha.2013.06.029.

21. Keenum Z, McGwin G Jr, Witherspoon CD, Haller JA, Clark ME, Owsley C. Patients' adherence to recommended follow-up eye care after diabetic retinopathy screening in a publicly funded county clinic and factors associated with follow-up eye care use. JAMA Ophthalmol. 2016;134(11):1221-1228. doi:10.1001/jamaophthalmol.2016.3085.

22. Russo A, Morescalchi F, Costagliola C, Delcassi L, Semeraro F. A novel device to exploit the smartphone camera for fundus photography. J Ophthalmol. 2015;2015:823139. doi:10.1155/2015/823139.

23. Poplin R, Varadarajan AV, Blumer K, et al. Prediction of cardiovascular risk factors from retinal fundus photographs via deep learning. Nat Biomed Eng. 2018;2(3):158-164. doi:10.1038/s41551-018-0195-0.

24. Tozer K, Woodward MA, Newman-Casey PA. Telemedicine and diabetic retinopathy: review of published screening programs. J Endocrinol Diabetes. 2015;2(4):1-10. doi:10.15226/2374-6890/2/4/00137.